Pharmaceuticals & Therapeutics

Tectonic Therapeutic reports key clinical progress in two distinct rare diseases, backed by a strong cash position and new leadership for its next phase.

Structure Therapeutics reports strong Phase 2 data for its oral obesity pill, aleniglipron, positioning it as a key contender in the race for pill-based GLP-1s.

The 3M spin-off navigates a transformative year, posting strong organic growth driven by MedSurg and Dental, despite a reported sales dip from divestitures.

With Phase 3 epilepsy results for its lead drug azetukalner due in March, Xenon reveals a major R&D spend and a cash runway to fuel its broad pipeline.

With clinical results converging, a new report reveals the real GLP-1 battle is fought in patent filings, not labs, deciding who wins this $100B+ market.

Biotech giant Regeneron extends its sponsorship of America's top high school science contest, securing its legacy and boosting access for a new generation.

A key partnership ensures the supply of a breakthrough therapy for FOP, a devastating condition where muscle turns to bone, highlighting a new era in drug production.

With promising data for its oral STAT6 degrader and a cash runway into 2029, Kymera Therapeutics is poised to disrupt the injectable-dominated market.

Kairos Pharma aims to reshape lung cancer treatment by acquiring two AI-designed drugs, targeting a key resistance mechanism in a multi-billion dollar market.

With a key FDA decision looming and pivotal data on a second therapy imminent, Viridian is poised to reshape the multi-billion dollar Thyroid Eye Disease market.

As colorectal cancer rates rise in younger adults, advocates demand provinces lower the screening age. But will policymakers act on the growing evidence?

After a strong 2025, Viatris unveils a plan for $650M in savings, a 10% workforce cut, and a focus on six new drugs to fuel future innovation.

Perrigo takes a massive $1.3B impairment charge and plans a 7% workforce reduction as it pivots to a 'CORE' business amid a challenging outlook.

The environmental services giant surpassed 2025 targets, driven by its GreenUp strategy, major acquisitions in water tech, and a renewed global push.

MiMedx reports record 2025 sales and a $100M buyback, but faces a major challenge from new Medicare reimbursement rules set to disrupt the wound care market.

With stellar clinical data and a full war chest, Terns is hitting the road to convince investors its leukemia drug, TERN-701, is a true disruptor.

With cash to last until 2027 but mounting losses, Alector stakes its future on its ABC platform and a pivotal Alzheimer's trial milestone.

Struggling biotech Jupiter Neurosciences presents its Parkinson's drug to elite investors at Mar-a-Lago, betting its hybrid business model can win funding.

Rgenta Therapeutics unveils a promising oral drug that targets the genetic root of Huntington's, offering a new beacon of hope for patients.

Investors sue Corcept Therapeutics, claiming the company hid FDA warnings about its key drug, relacorilant, before a 50% stock price collapse.